Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial

A new quinolone, zabofloxacin, has now been developed; hence, a non-inferiority trial is needed to compare this new compound with another widely used quinolone to examine its efficacy and safety for the treatment of chronic obstructive pulmonary disease (COPD) exacerbations. This was a prospective,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Chron Obstruct Pulmon Dis
Egile Nagusiak: Rhee, Chin Kook, Chang, Jung Hyun, Choi, Eu gene, Kim, Hyun kuk, Kwon, Yong-Soo, Kyung, Sun Young, Lee, Ji-Hyun, Park, Myung Jae, Yoo, Kwang Ha, Oh, Yeon Mok
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2015
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622522/
https://ncbi.nlm.nih.gov/pubmed/26543359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S90948
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak